17 Apr

Doctor Julià Panés joins the GoodGut Board of Advisors

Doctor Julià Panés joins the GoodGut Board of Advisors

GoodGut has a new member of its Board of Advisors: Dr Julià Panés, a well-known specialist in inflammatory bowel disease (IBD). Panés is the director of the IBD research group at the August Pi i Sunyer Biomedical Research Institute (Idibaps) and head of the IBD Unit at Barcelona’s Hospital Clínic. His team publishes an average of 20 scientific articles a year in prestigious journals such as the New England Journal of Medicine, Lancet and Gastroenterology

Panés has had an illustrious career: over 300 publications, 500 conference speeches and membership of global gastroenterology organisations such as the American Gastroenterological Association (AGA), United European Gastroenterology (UEG), European Chron’s and Colitis Organisation (ECCO) and International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). He is also a lecturer at the University of Barcelona. In 2013 he received the Award for Professional Excellency from the Barcelona College of Doctors (Col·legi de Metges).

Panés is the fourth member of GoodGut’s Board of Advisors, alongside the doctors Antoni Castells and Fermín Mearin, and the entrepreneur Gabriel Masfuroll.

GoodGut is developing various non-invasive tests based on intestinal microbiota for early diagnosis of digestive diseases, such as RAID-CD for IBD and irritable bowel syndrome.

14 Mar

21ª Reunión de la Asociación Española de Gastroenterología

21ª Reunión de la Asociación Española de Gastroenterología

Fecha: del 14 al 16 de marzo de 2018
Lugar: Hotel Meliá Castilla · Madrid

En la 21ª Reunión de la Asociación Española de Gastroenterología se presentarán los mejores trabajos de investigación y se abordarán temas de actualidad a través del programa científico en el cual participará activamente GoodGut:

“RAID-IBS Diagnosis: un nuevo método no invasivo para el diagnóstico del síndrome del intestino irritable” (15 de marzo – De 8.20 h a 8.30 h)

“RAID-CRC: el uso de una firma bacteriana en heces como nueva herramienta para el cribado del cáncer colorrectal” (15 de marzo – De 9.45 h a 9.55 h)

“RAID-CD Monitor: nuevo método no invasivo para determinar la actividad endoscópica en pacientes con enfermedad inflamatoria intestinal” (16 de marzo – De 11.30 h a 11.40 h)

Además GoodGut presentará un póster en la sección de oncología gastrointestinal:

“Biomarcadores específicos para cáncer colorrectal y EII presenta abundancias parecidas en portadores del síndrome de Lynch sanos y pacientes con lesiones cancerosas”

Más información


10 Mar

GUT Microbiota For Health World Summit 2018

GUT Microbiota For Health World Summit 2018

Date: 10-11 March, 2018
Place: Barceló Aran Mantegna Hotel · Rome (Italy)

GUT Microbiota For Health World Summit 2018 will provide clinical researchers and healthcare professionals. The event will host a selection of plenary sessions and smaller group workshops with participation of an elite worldwide group of health care professionals looking to get up to date on the latest clinical applications of gut microbiota.

GoodGut will present four posters:

“RAID-CRC: a new non-invasive tool for colorectal cancer screening based on bacterial signatures”
“RAID-IBS Diagnosis: a new non-invasive method to support the irritable bowel syndrome diagnosis”
“RAID-CD Monitor: a new non-invasive method to determine endoscopic activity in inflammatory bowel disease”
“Faecal biomarkers show similar abundances in healthy Lynch syndrome and patients with colorectal cancer”

More information

16 Feb

The GoodGut colon cancer test, one of the projects to be supported by the CIMTI

The GoodGut colon cancer test, one of the projects to be supported by the CIMTI

The Centre for the Integration of Medicine and Innovative Technologies (CIMTI), created in 2017 at the initiative of the Leitat Foundation with the support of the Catalan Department of Health and the Agency for Health Quality and Assessment of Catalonia, has selected GoodGut’s RAID-CRC test as one of the health innovation projects that will improve patient quality of life.

The RAID-CRC test is a non-invasive method which will be used to prevent and diagnose colorectal cancer more effectively and reduce the need for unnecessary colonoscopies. Positive results from the first clinical trial were recently published.

The projects supported by the CIMTI are in the development phase and have been selected “with great care, focusing on those which may have a significant overall impact on health and which are viable” explained Manel Balcells, director of the centre.

The CIMTI has a collaboration agreement with the CIMIT in Boston, one of the most important centres in the world for medical innovation and on which the CIMTI is modelled.

All of the projects selected which are already up and running were launched by public hospitals and the CIMTI will now support them to find further funding: “There are already private investors interested in funding these projects, and the CIMTI acts as an intermediary”, Balcells told us. In the case of GoodGut, a 4 million euro funding round has been opened to bring the new test to the market before the end of 2019.

For further information read the following news items on Ara (in Catalan) and La Vanguardia (in Spanish) websites.

06 Feb

Dr Castells: “We need to anticipate the appearance of colorectal cancer”

Dr Castells: “We need to anticipate the appearance of colorectal cancer”

Doctor Antoni Castells, specialist in gastroenterology, is medical director of Barcelona’s Hospital Clínic, co-coordinator of the Barcelona’s colorectal cancer detection programme and medical adviser to the biotechnology company GoodGut. In the research field, Castells leads the Gastrointestinal and Pancreatic Oncological Research Group of the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and of the Liver and Digestive Diseases Biomedical Research Centre (CIBERehd). We are interviewing him because GoodGut has just presented the first positive results from the clinical trial conducted of the new non-invasive RAID-CRC test for preventing and diagnosing colon and rectal cancer, which could be on the market in 2019.

What are the most pressing challenges in combating colorectal cancer?

In my opinion we are currently facing three main generic challenges in the research against colon and rectal cancers. The first is to try to make treatments more effective and less toxic, an area in which significant progress has been made in recent years and where the prognosis has improved. The second is to seek less invasive diagnostic methods. Currently the main method is via colonoscopy, an excellent and very effective test, but one which is invasive and requires preparation meaning that, although rare, the procedure may lead to complications. The third is to anticipate the appearance of cancer and implement strategies helping us to prevent it. We need to detect it at an earlier phase, when it is what we call a polyp or adenoma, to prevent the lesion progressing to become cancer.

Are these challenges faced worldwide?

Yes, in most developed countries we are more or less at this same preventive or prevention research stage.

Is the primary state of the polyp not currently diagnosed?

Yes, we have various ways of detecting it in this phase. The most effective is the colonoscopy. As I was saying before, this is a tool that is used a lot because very small lesions, such as polyps, can be detected. Then there are other methods to identify persons with a high probability of having this lesion, to find out whether it is worth carrying out a colonoscopy. Of these methods, which we call markers, the most normal is detecting blood in stools. Finding blood in stools can mean many other things, not necessarily either a polyp or cancer, but we feel that if found it is worth carrying out a colonoscopy on this person. The research by companies such as GoodGut is offering us other markers, at different phases of development and market readiness, which have the same purpose but are not invasive and are more efficient.

What is your assessment of the situation for preventive programmes in Catalonia?

Ten years ago they did not exist, or maybe there were was a pilot study; today the whole population of Catalonia is covered by these programmes which have proven to reduce the mortality rate for colon cancer. As a country we should be pleased we have them. However, for any preventive or therapeutic programme it is also possible to seek even more sensitive and specific strategies that improve mortality and save resources, such as the new test GoodGut is developing.


“The initial results demonstrate that the RAID-CRC is a more specific test than the faecal occult test”

You are a member of the advisory board of GoodGut, the biotechnology company which is developing the RAID-CRC test. How will this test contribute to progress in preventing and diagnosing colon and rectal cancer?

This test is extremely innovative because it is the first time markers deriving from the bacteria present in the gut are used to identify persons with cancer or polyps. We do not really know if the changes in flora precede the cancer or if the cancer changes the flora but, whatever the case, what we see is that these microbial markers identify the persons who have these lesions. The current results, which are still very early, demonstrate this correlation. If these results are confirmed with larger studies, especially in populations without symptoms or any type of manifestation leading them to think they may have cancer, which is the population we consider ideal for screening or prevention, the RAID-CRC could be a more specific test than the current faecal occult blood test. This would reduce unnecessary colonoscopies for those who give a positive result in the blood test and do not actually have cancer, with the benefits this provides for both the person and the health system.

Will the RAID-CRC now be validated in a wider population?

Yes, a validation study will begin shortly on 2,500 people in Germany, a country where colorectal cancer is prevented by means of colonoscopy. This will provide us with colonoscopies from persons with cancer or polyps and those who are healthy. This will allow us to validate the usefulness of the RAID-CRC.

If the results of the final study are positive, will Catalonia again be at the forefront of an advance in biomedical research?

In the field of preventing colon cancer, we are in an excellent position. If the results obtained so far are confirmed with this larger cohort of persons with risk of colon cancer, the country’s position will certainly be consolidated around the world.

According to the World Health Organisation, colorectal cancer is the third most common form of cancer in the world.

That is correct, what happens is that the frequency changes significantly according to country. For example, if we take only Western European countries, the United States and Asia, it is not only the third most common, but becomes the second for women and third for men.

Can you make a future prediction about its incidence?

The tendency we have seen in recent years in most countries without colorectal cancer screening is that the incidence has risen. What we are also starting to see is that in countries that have set up preventive programmes the incidence has stabilised and there are signs that in some it is beginning to fall.

Photo: Hospital Clínic

19 Jan

GoodGut does trials on more effective test to prevent colon cancer

GoodGut does trials on more effective test to prevent colon cancer

GoodGut has presented positive results for the RAID-CRC test which will improve early detection of colorectal cancer (CRC). This test yields 55% fewer false positives than screening with faecal occult blood tests, as blood is not a specific marker of CRC and, as a result, limits the number of colonoscopies that must be given.

These conclusions are from a multi-centre study with 450 patients with symptoms pointing to CRC who had had a colonoscopy at five Catalan hospitals that are leaders in oncology: Dr Josep Trueta University Hospital, Bellvitge University Hospital, Catalan Institute of Oncology, Healthcare Institute (IAS) and the Hospital Consortium of Vic.

Currently, the main colon-cancer screening programme in many countries is the immunochemical faecal occult blood test (FIT–Kit OC-Sensor®). This test is effective and affordable, but has a low positive predictive value (8%), which means it yields a high percentage of false positives leading to unnecessary colonoscopies. RAID-CRC complements the current screening with the microbiological signature of CRC in the faecal sample.

“The results of the study prove that screening with RAID-CRC and FIT detects CRC with up to 94% sensitivity and advanced neoplasms with 80% sensitivity,” explains Dr Xavier Aldeguer, GoodGut medical director and head of the Digestive System Department at Dr Josep Trueta University Hospital in Girona. Aldeguer has been researching the intestinal microbiota for more than 10 years.

Furthermore, Dr Antoni Castells, co-coordinator of the Barcelona colorectal cancer detection programme, says the new approach would “reduce the number of unnecessary colonoscopies by 32% and detect 59% of precancerous lesions“. The savings associated with colonoscopies alone would add up to more than €5.5 million per round of screening every two years and increase the sensitivity to detect precancerous lesions (diagnosing the disease in a very early stage).

Third most common form of cancer in the world

CRC is the third most common form of cancer in occurrence and mortality rate in the world, according to the World Health Organisation (WHO). Each week, more than 8,600 new cases of colon cancer are diagnosed in Europe and 2,500 in the United States. This is why population screening policies have been implemented to detect the disease early with non-invasive tools.

Using RAID-CRC “will have a significant positive impact on society, as the current screening system is more diagnostic than preventative,” says Mariona Serra, CEO of GoodGut. Serra also explains that the next step is validating these results in a larger sample of patents and after will allow the company to get CE marking for the test and take it to market by the end of 2019.

08 Nov

Jornada “StartUp Girona”

Jornada “StartUp Girona”

Jornada “Empreses Emergents i Finançament” StartUp Girona

Dia/Mes: 8 de novembre

Hora: 12:25 h a 13:20 h


  • Francesc Destrée, cofundador de Xerpa d’Andorra
  • Joan Folguera, director executiu INTECH3D de Lleida
  • Mariona Serra, Goodgut de Girona
  • Julià Carboneras, Conductr de Girona
  • Josep Gala, CIB (Culinary Institute of Barcelona)
  • Paul Costaseca, Flipr de Perpinyà
  • Moderador: Sr. Jaume Fàbrega, vicepresident de la Cambra de Comerç de Girona

Lloc: Auditori – Palau de Congressos de Girona

Més informació

10 Oct

GoodGut moves to new premises at Science and Technology Park of Girona

GoodGut moves to new premises at Science and Technology Park of Girona

GoodGut has moved to a new space at Science and Technology Park of Girona: equipped with the latest technology, such as class II biosafety cabinets, it makes for easier interaction among the team of scientists and business development professionals.

This change comes at a key moment for the biotechnology company, which is getting ready to present the clinical results of its pipeline of non-invasive systems for improving early diagnosis of colon cancer, Crohn’s disease and ulcerative colitis, among other inflammatory bowel diseases (IBD). GoodGut is aiming to have these products on the market by 2019.

GoodGut was created in 2014 as a spin-off of University of Girona and Biomedical Research Institute of Girona Dr Josep Trueta by Mariona Serra, Xavier Aldeguer and Jesús Garcia-Gil. “It is very important to us to work in a scientific and business environment in a city as attractive as Girona and be at the heart of an internationally-recognised life sciences cluster like the BioRegion of Catalonia” says Mariona Serra, CEO of the company. Today there are over 140 companies, research groups and institutions based at the UdG Park.

10 Oct

GoodGut launches a new website with its digestive health pipeline

GoodGut launches a new website with its digestive health pipeline

Digestive diseases have a high incidence rate and have a chronic and serious impact on the daily life of sufferers. GoodGut has just launched a new website (www.goodgut.eu), with the slogan Enhancing Digestive Health, on which it presents its pipeline of non-invasive and prebiotic systems for improving the diagnosis and treatment of conditions including colon cancer, Crohn’s disease, and ulcerative colitis. These products are in the clinical trial phase, with plans for them tol be put on the market in 2019.

This intuitive new website provides the user with full corporate information: the company; mission, vision and values; Management and Board of Advisers; strategic and scientific partners; social responsibility, and a page dedicated to careers.

It also includes two update sections: the latest news from the company and a blog to disseminate knowledge of the research and development of GoodGut and digestive diseases in general.

Innovation based on intestinal microbiota

GoodGut’s know-how is based on the study of the intestinal microbiota of individuals, a determining factor in the immune system of the intestine and the development of digestive diseases. The company offers pioneering technological solutions for obtaining a faster, more reliable and cheaper medical diagnosis than using existing methods, and treatments to improve the quality of life of patients with compromised digestive health.

GoodGut was created in 2014 as a spin-off of University of Girona and Biomedical Research Institute of Girona Dr Josep Trueta by Mariona Serra, Xavier Aldeguer and Jesús Garcia-Gil. The company is based in the Science and Technology Park of Girona and forms part of CataloniaBio, the Catalan association of health and life sciences companies.